Navigation Links
Pharmasset Receives Notice of Allowance
Date:6/26/2008

o 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 50 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice-daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

We have commenced dosing two additional cohorts of this 4-week Phase 1 study. Cohort 3 will continue dose-exploration with administration of R7128 1000mg twice-daily (BID) with Pegasys plus Copegus in treatment-naive patients with HCV genotype 1. Cohort 4 will evaluate R7128 1500mg BID with Pegasys plus Copegus in treatment-experienced patients with genotypes 2 or 3 who did not achieve a sustained virologic response (SVR) with previous interferon-based therapy.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically inf
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, ... 2014, court documents indicate that 1,183 claims had been ... developed gynecomastia (male breast growth) and other complications allegedly ... that this represents an increase of more than 100 ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
... TUESDAY, Nov. 8 (HealthDay News) -- Despite concerns that the ... confuse older Americans, a new study finds seniors are able ... The researchers found evidence that seniors -- possibly with the ... as necessary. The findings may ease concerns among some ...
... Reporter , TUESDAY, Nov. 8 (HealthDay News) -- The latest ... might be better than other such scales at spotting people ... Columbia-Suicide Severity Rating Scale (C-SSRS) was developed eight years ago ... The new study, appearing online Nov. 8 in the ...
... What do Moby Dick, the Salem witch trials and alien ... sleep paralysis. Less than 8 percent of the general population ... groups -- students and psychiatric patients -- according to a ... of Pennsylvania. Sleep paralysis is defined as "a discrete period ...
... A team of Virginia Commonwealth University pediatric surgeons today successfully ... Tapia of the Dominican Republic. The complex, 20-hour ... surgery of its kind at the Children,s Hospital of Richmond ... in the VCU Department of Surgery and surgeon-in-chief, the team ...
... , PHILADELPHIA Thomas Jefferson University Hospital is ... to offer the recently-approved U.S. Food and Drug Administration ... BRAF mutation (which occurs in about half of all ... new, potentially life-saving drug. In August, the ...
... , TUESDAY, Nov. 8 (HealthDay News) -- Health care ... hands before and after treating their patients, new research shows. ... of Infection Control and Hospital Epidemiology , this lapse ... settings because some germs can get through latex gloves or ...
Cached Medicine News:Health News:Seniors Choose Medicare Prescription Plans Wisely: Study 2Health News:Suicide Checklist Spots People at Highest Risk 2Health News:Suicide Checklist Spots People at Highest Risk 3Health News:Psychologists chase down sleep demons 2Health News:VCU performs separation surgery on conjoined twins 2Health News:VCU performs separation surgery on conjoined twins 3Health News:Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Hinged Ulnar Deviation Splint uses safe, mild ... with ulnar deviation at the MP joints. ... pinch. Radial and ulnar polycentric hinges located ... and extension. Padded, malleable finger rings can ...
... RCAI Dorsal Blocking Splint is constructed of a ... DBS protects the flexor tendons of the hand ... scar tissue development in the later stages of ... dorsally on the hand and positions the wrist ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
Medicine Products: